CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

Inclusion Criteria

• •Only For B-ALL
• •1. No gender or age limit
• •2. Histologically confirmed diagnosis of CD69b+ B-ALL per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Myeloid Leukemia (2016.v1);
• •3. Relapsed or refractory CD123+ AML (meeting one of the following conditions):
• •1. CR not achieved after standardized chemotherapy;
• •2. CR achieved following the first induction, but CR duration is less than 12 months;
• •3. Ineffectively after first or multiple remedial treatments;
• •4. 2 or more relapses;
• •4. The number of primordial cells in bone marrow is \> 5% (by morphology), and/or \> 0.01% (by flowcytometry);
• •5. Philadelphia chromosome negative(Ph-) subjects; Ph+ subjects who cannot tolerate tyrosine kinase inhibitor (TKI) treatment or who do not respond to two kinds of TKI treatment;
• •Only For B-NHL
• •1. No gender or age limit;
• •2. Histologically confirmed diagnosis of DLBCL (NOS), FL, DLBCL transformed from CLL/SLL, PMBCL, and HGBCL per the WHO Classification Criteria for Lymphoma (2016);
• •3. Relapsed or refractory B-NHL (meeting one of the following conditions):
• •<!-- -->
• •1. No response or relapse after second-line or above chemotherapy regimens;
• •2. Primary drug resistance;
• •3. Relapse after auto-HSCT;
• •4. At least one assessable tumor lesion per Lugano 2014 criteria
• •For both B-ALL and B-NHL
• •1. Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit ofnormal, creatinine ≤ 176.8 umol/L;
• •2. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;
• •3. No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%;
• •4. Estimated survival time ≥ 3 months;
• •5. ECOG performance status 0 to 2;
• •6. Patients or their legal guardians volunteer to participate in the studyand sign the informed consent.